The MASAI trial — AI-supported mammography screening, randomised controlled evidence

evidence

MASAI is a randomised, controlled, non-inferiority, single-blinded, population-based screening trial in Sweden enrolling over 100,000 women. Reported results include a 29% higher screen-detected cancer detection rate with AI support, a 44.2% reduction in screen-reading workload (48,444 fewer readings), false-positive counts of 772 (1.5%) in the intervention arm against 765 (1.4%) in the control arm, and in the full results a non-inferior interval-cancer rate reported as about 12% lower, higher sensitivity, unchanged specificity and fewer interval cancers with unfavourable characteristics. V55 verification basis: none of the three papers was fetched — thelancet.com and sciencedirect.com are blocked to this session. The figures and the trial design were carried in search results attributing them to the named Lancet titles and to institutional press material about them; the publication dates of the final results are reported variously as late 2025 and early 2026 and were NOT resolved, and no DOI is asserted.

A evidence is not a place. Drawing it on a map would assert something about the world that no stored fact supports.